2017
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial
Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vanqa N, Bell-Mandla N, Smith P, Floyd S, Bock P, Ayles H, Beyers N, Donnell D, Fidler S, Hayes R, Hauck K, Team H, Hargreaves J, Watson-Jones D, Godfrey-Faussett P, Cori A, Pickles M, Mandla N, Yang B, James A, Vermaak R, Makola N, Hoddinott G, Naidoo V, Bond V, Simwinga M, Mwinga A, Kosloff B, Limbada M, Bwalya J, Ngulube C, Fraser C, Eshleman S, Agyei Y, Cummings V, Catalano D, Emel L, Bunts L, Noble H, Burns D, Kouda A, Sista N, Moore A, White R, Headen T, Miller E, Hinson K, Vermund S, Barnes M, Horn L, Mwango A, Baldwin M, Wolf S, Hughes E. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. The Lancet Global Health 2017, 5: e1133-e1141. PMID: 28964756, PMCID: PMC5640509, DOI: 10.1016/s2214-109x(17)30367-4.Peer-Reviewed Original ResearchConceptsHIV-negative peopleHIV-positive individualsHIV-negative individualsAntiretroviral therapyHealth-related qualityHIV careHRQoL scoresHIV statusHerpes simplex virus type-2 statusNational InstituteHPTN 071 (PopART) studyHPTN 071 (PopART) trialLaboratory-confirmed HIVType 2 statusCross-sectional baseline surveyLarge cross-sectional surveyRecreational drug useCross-sectional surveyPresident's Emergency PlanGeneral population sampleHRQoL informationBetter HRQoLHIV-negativeHIV progressionHRQoL data
2015
Exploring Social Networking Technologies as Tools for HIV Prevention for Men Who Have Sex With Men.
Ramallo J, Kidder T, Albritton T, Blick G, Pachankis J, Grandelski V, Kershaw T. Exploring Social Networking Technologies as Tools for HIV Prevention for Men Who Have Sex With Men. AIDS Education And Prevention 2015, 27: 298-311. PMID: 26241381, PMCID: PMC5486219, DOI: 10.1521/aeap.2015.27.4.298.Peer-Reviewed Original Research
2013
The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2011
High levels of acceptability of couples-based HIV testing among MSM in South Africa
Stephenson R, Rentsch C, Sullivan P. High levels of acceptability of couples-based HIV testing among MSM in South Africa. AIDS Care 2011, 24: 529-535. PMID: 22007940, PMCID: PMC3279614, DOI: 10.1080/09540121.2011.617413.Peer-Reviewed Original ResearchConceptsCVCT servicesCouples-based HIV testingHIV-negative menVoluntary HIV counselingHIV testing servicesMale sex partnersYears of ageHIV counselingHIV testingSex partnersMSMTesting servicesMenHeterogeneous populationFuture studiesSame-sex male relationshipsCurrent residenceHigh acceptanceHigh levelsAcceptabilityHigher numberCVCTYearsBehavioral characteristicsCentral Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden
Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW. Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. The Journal Of Infectious Diseases 2011, 204: 753-760. PMID: 21844301, PMCID: PMC3156103, DOI: 10.1093/infdis/jir387.Peer-Reviewed Original ResearchConceptsWhite blood cell countCSF HIV RNAPrimary HIV infectionHIV RNACerebrospinal fluidPHI participantsImmune activationAlbumin ratioPrimary human immunodeficiency virus-1 infectionCentral nervous system immune activationCSF white blood cell countHuman immunodeficiency virus-1 (HIV-1) infectionHuman immunodeficiency virus (HIV) infectionHigher albumin ratioHIV-seronegative controlsImmunodeficiency virus infectionHIV-seronegative participantsCells/μLLow cerebrospinal fluidBlood cell countVirus-1 infectionCross-sectional studyMagnitude of infectionCXCL10 concentrationsPHI patientsTipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone
Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone. The American Journal Of Drug And Alcohol Abuse 2011, 37: 224-228. PMID: 21438849, DOI: 10.3109/00952990.2011.568081.Peer-Reviewed Original ResearchConceptsTPV/rSteady-state pharmacokinetic evaluationGlucuronide metabolitesBUP/naloxoneHIV-negative subjectsHIV-seronegative subjectsBuprenorphine/naloxoneSteady-state pharmacokineticsCytochrome P450 3A4Ritonavir effectsPharmacodynamic consequencesPharmacokinetic evaluationBuprenorphineNorBUPCombined inhibitionNaloxoneCurve AUCP450 3A4AUCSignificant increasePharmacokineticsTipranavirPrevious reportsSubjectsMetabolites
2010
Determinants of Individual Variation in Intracellular Accumulation of Anti-HIV Nucleoside Analog Metabolites
Paintsil E, Dutschman GE, Hu R, Grill SP, Wang CJ, Lam W, Li FY, Ghebremichael M, Northrup V, Cheng YC. Determinants of Individual Variation in Intracellular Accumulation of Anti-HIV Nucleoside Analog Metabolites. Antimicrobial Agents And Chemotherapy 2010, 55: 895-903. PMID: 21078952, PMCID: PMC3028801, DOI: 10.1128/aac.01303-10.Peer-Reviewed Original ResearchConceptsNucleoside analoguesPeripheral blood mononuclear cellsAntiretroviral drug discoveryThymidine kinase 1 activityBlood mononuclear cellsConcentrations of AZTMetabolite concentrationsIntracellular concentrationAntiretroviral therapyClinical responseMononuclear cellsHealthy donorsHIV therapyTherapy needTriphosphate metaboliteAZT monophosphateAnalogue metabolitesCellular kinasesCassette (ABC) transport proteinsInverse correlationDemographic characteristicsAZTIntracellular accumulationKinase 1 activityIndividual variationCerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation
Probasco JC, Deeks SG, Lee E, Hoh R, Hunt PW, Liegler T, Price RW, Spudich SS. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS 2010, 24: 1001-1005. PMID: 20299968, DOI: 10.1097/qad.0b013e328331e15b.Peer-Reviewed Original ResearchConceptsHIV RNA levelsViral controllersIntrathecal inflammationCSF white blood cell countUndetectable plasma HIV RNA levelsCerebrospinal fluid HIV RNACSF HIV RNA levelsPlasma HIV RNA levelsTreatment-mediated viral suppressionWhite blood cell countCSF HIV infectionIP-10 concentrationsRNA levelsChronic systemic inflammationSubset of HIVHIV-1 RNAPlasma albumin ratioAbsence of therapyBlood cell countCentral nervous systemCross-sectional analysisCSF neopterinViremic HIVHIV RNAViral suppressionEstimation of the number of injection drug users in St. Petersburg, Russia
Heimer R, White E. Estimation of the number of injection drug users in St. Petersburg, Russia. Drug And Alcohol Dependence 2010, 109: 79-83. PMID: 20060238, PMCID: PMC2875272, DOI: 10.1016/j.drugalcdep.2009.12.010.Peer-Reviewed Original ResearchPsychiatric and Substance Abuse Comorbidity among HIV Seropositive and HIV Seronegative Prisoners in Malaysia
Zahari MM, Bae W, Zainal NZ, Habil H, Kamarulzaman A, Altice FL. Psychiatric and Substance Abuse Comorbidity among HIV Seropositive and HIV Seronegative Prisoners in Malaysia. The American Journal Of Drug And Alcohol Abuse 2010, 36: 31-38. PMID: 20141394, PMCID: PMC4847714, DOI: 10.3109/00952990903544828.Peer-Reviewed Original ResearchConceptsHIV infectionSubstance abusePsychiatric illnessPsychiatric disordersTriple diagnosisPsychiatric diagnosisDrug useMental illnessSubstance abuse comorbidityInjection drug useCross-sectional studyStructured Clinical InterviewSubstance use disordersPublic health approachMental Disorders-IVHIV-seropositiveOpioid dependencePotential confoundersDiagnostic Statistical ManualUse disordersDual diagnosisClinical InterviewAdequate careCommunity settingsHealth approach
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLXWU Polyomavirus in Patients Infected with HIV or Hepatitis C Virus, Connecticut, USA, 2007 - Volume 15, Number 7—July 2009 - Emerging Infectious Diseases journal - CDC
Miller MA, Weibel C, Ferguson D, Landry ML, Kahn JS. WU Polyomavirus in Patients Infected with HIV or Hepatitis C Virus, Connecticut, USA, 2007 - Volume 15, Number 7—July 2009 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2009, 15: 1095-1097. PMID: 19624928, PMCID: PMC2744261, DOI: 10.3201/eid1507.090150.Peer-Reviewed Original ResearchAnal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand
Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J. Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. Sexually Transmitted Infections 2009, 85: 503. PMID: 19525263, PMCID: PMC3875384, DOI: 10.1136/sti.2009.036707.Peer-Reviewed Original ResearchConceptsAnal squamous intraepithelial lesionsHigh-grade squamous intraepithelial lesionsLow-grade squamous intraepithelial lesionsHIV-negative MSMSquamous intraepithelial lesionsHIV-positive MSMNegative MSMHIV-negative menIntraepithelial lesionsPositive MSMRisk factorsAnal condylomaNegative menActive antiretroviral therapy (HAART) useAbnormal anal cytologyAnal cancer precursorsAnal Pap smearsAnal precancerous lesionsAntiretroviral therapy useT-cell countsAtypical squamous cellsSignificant risk factorsAnal cytologyAsian HIVTherapy useImpact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans.
Crothers K, Goulet JL, Rodriguez-Barradas MC, Gibert CL, Oursler KA, Goetz MB, Crystal S, Leaf DA, Butt AA, Braithwaite RS, Peck R, Justice AC. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Education And Prevention 2009, 21: 40-53. PMID: 19537953, PMCID: PMC3118467, DOI: 10.1521/aeap.2009.21.3_supp.40.Peer-Reviewed Original ResearchConceptsHIV-negative veteransIncidence rate ratiosSmoking statusHIV-negative patientsSimilar mortality riskHIV-positive veteransComorbid diseasesCurrent smokingOverall mortalityCigarette smokingPoor outcomeMortality riskHIVPoisson regressionMortalitySmokingRate ratioVeteransDiseaseStudy of mechanismsLow levelsStatusSmokersPatientsCessation
2008
Spatial distribution of HIV prevalence and incidence among injection drugs users in St Petersburg: implications for HIV transmission
Heimer R, Barbour R, Shaboltas AV, Hoffman IF, Kozlov AP. Spatial distribution of HIV prevalence and incidence among injection drugs users in St Petersburg: implications for HIV transmission. AIDS 2008, 22: 123-130. PMID: 18090400, PMCID: PMC2778790, DOI: 10.1097/qad.0b013e3282f244ef.Peer-Reviewed Original ResearchMeSH KeywordsHeroinHIV InfectionsHIV SeronegativityHumansIncidenceNeedle SharingPrevalenceRisk AssessmentRussiaSubstance Abuse, IntravenousUrban PopulationConceptsInjection drug usersDrug usersReceptive syringe sharingRisk behavior dataHIV/AIDS epidemicRisky injection behaviorsSeronegative cohortsSeronegative individualsHeroin injectionHIV prevalenceHIV transmissionIncident casesSyringe sharingHIV epidemicVaccine studiesStudy populationDrug useResidential addressesStudy participantsEpidemiological analysisHIVPrevalenceAIDS epidemicDisease prevalenceCohort
2007
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Neuwelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals Of Oncology 2007, 18: 1851-1855. PMID: 17804469, DOI: 10.1093/annonc/mdm340.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCombined Modality TherapyConsensusEye NeoplasmsFemaleHIV SeronegativityHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsPrimary intraocular lymphomaOverall survivalMedian timeFocal therapyPrimary central nervous system lymphomaMedian ECOG performance statusCentral nervous system lymphomaTreatment typeECOG performance statusPositive CSF cytologyNervous system lymphomaBrain relapseMedian PFSMedian progressionPIOL patientsUncommon subsetIntraocular lymphomaPerformance statusRelapse patternsRetinal biopsyTreatment toxicityMedian ageSystem lymphomaInitial treatmentCSF cytologyThe Association Between History of Violence and HIV Risk A Cross-Sectional Study of HIV-Negative Incarcerated Women in Connecticut
Ravi A, Blankenship KM, Altice FL. The Association Between History of Violence and HIV Risk A Cross-Sectional Study of HIV-Negative Incarcerated Women in Connecticut. Women's Health Issues 2007, 17: 210-216. PMID: 17570681, DOI: 10.1016/j.whi.2007.02.009.Peer-Reviewed Original ResearchConceptsUnprotected sexUnprotected sex practicesNonprimary partnersHistory of violencePrimary partnersSex practicesMale primary partnerIncarcerated womenMultivariate logistic regressionHIV prevention interventionsHIV prevention agendaHIV infectionSectional studyHIV riskPrevention interventionsFuture longitudinal researchHealth historyDrug useSexual partnersLogistic regressionRisk APrevention agendaPhysical violenceWomenWomen's background
2006
Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increaseIncreased COPD Among HIV-Positive Compared to HIV-Negative Veterans
Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, Team F. Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans. CHEST Journal 2006, 130: 1326-1333. PMID: 17099007, DOI: 10.1378/chest.130.5.1326.Peer-Reviewed Original ResearchConceptsInjection drug usePrevalence of COPDHIV-negative subjectsIndependent risk factorHIV infectionICD-9 codesRisk factorsDiagnostic codesAlcohol abuseICD-9 diagnostic codesHIV-negative veteransActive antiretroviral therapyHIV-positive patientsEra of HAARTHIV-negative menHIV-positive subjectsProspective observational studyPathogenesis of COPDRisk of COPDHealth care providersElectronic medical recordsRace/ethnicityAntiretroviral therapyHIV-positiveCigarette smoking
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply